At the end of the latest market close, AbCellera Biologics Inc. (ABCL) was valued at $11.67. In that particular session, Stock kicked-off at the price of $12.30 while reaching the peak value of $12.345 and lowest value recorded on the day was $11.63. The stock current value is $11.02.Recently in News on December 7, 2021, AbCellera Announces Changes to Its Board of Directors. AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. You can read further details here
AbCellera Biologics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $14.79 on 01/03/22, with the lowest value was $11.01 for the same time period, recorded on 01/10/22.
AbCellera Biologics Inc. (ABCL) full year performance was -73.40%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, AbCellera Biologics Inc. shares are logging -80.04% during the 52-week period from high price, and 0.14% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $11.01 and $55.22.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 690462 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the AbCellera Biologics Inc. (ABCL) recorded performance in the market was -18.39%, having the revenues showcasing -24.81% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.36B, as it employees total of 206 workers.
Analysts verdict on AbCellera Biologics Inc. (ABCL)
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 15.93, with a change in the price was noted -5.76. In a similar fashion, AbCellera Biologics Inc. posted a movement of -34.06% for the period of last 100 days, recording 2,184,341 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ABCL is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
AbCellera Biologics Inc. (ABCL): Technical Analysis
Raw Stochastic average of AbCellera Biologics Inc. in the period of last 50 days is set at 2.09%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 2.96%. In the last 20 days, the company’s Stochastic %K was 12.70% and its Stochastic %D was recorded 15.47%.
Let’s take a glance in the erstwhile performances of AbCellera Biologics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -18.39%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -29.40%, alongside a downfall of -73.40% for the period of the last 12 months. The shares increased approximately by -4.81% in the 7-day charts and went up by -15.31% in the period of the last 30 days. Common stock shares were lifted by -24.81% during last recorded quarter.